Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: the influence of surgery and the cytostatic agent used.
Acute Kidney Injury
/ chemically induced
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Cytoreduction Surgical Procedures
Cytostatic Agents
/ therapeutic use
Female
Humans
Hyperthermia, Induced
Hyperthermic Intraperitoneal Chemotherapy
Neoplasm Recurrence, Local
/ therapy
Ovarian Neoplasms
/ drug therapy
Peritoneal Neoplasms
/ drug therapy
AKIN
Acute renal disease
EOC
HIPEC
RIFLE
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
28
01
2021
accepted:
13
07
2021
pubmed:
21
7
2021
medline:
12
11
2021
entrez:
20
7
2021
Statut:
ppublish
Résumé
The main objective of this study was to evaluate the differences between cisplatin and paclitaxel in the development of postoperative renal toxicity, using as a reference the RIFLE (Risk, Injury, Insufficiency, Loss, and End-stage renal function) and AKIN (Acute Kidney Injury Network) criteria in patients with primary or recurrent ovarian cancer with peritoneal dissemination treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). One hundred fifty-two patients who were treated between December 2007 and June 2017 were analyzed. Patients who received previous platinum-based chemotherapy had higher baseline creatinine levels than those who had not (p = 0.05). A total of 11 (7.2%) and 4 (2.6%) patients developed an acute renal dysfunction (ARD) during the postoperative period of cytoreduction and HIPEC according to the RIFLE and AKI criteria respectively. RIFLE detects a higher rate of ARD due to different parameters such as GFR (7.2% versus 2.6%, p = 0.016). Performing ostomy (p = 0.007; OR: 39.320; 95% CI = 2.74-56.13) and using of cisplatin during HIPEC treatment (p = 0.017; OR = 13.619; 95% IC = 1.600-25.95) were factors independently related to a higher rate of ARD. ARD has a multifactorial origin. Cisplatin was associated with the development of a higher rate of ARD than paclitaxel. Diagnosis of ARD did not correlate with worse survival figures.
Sections du résumé
BACKGROUND
BACKGROUND
The main objective of this study was to evaluate the differences between cisplatin and paclitaxel in the development of postoperative renal toxicity, using as a reference the RIFLE (Risk, Injury, Insufficiency, Loss, and End-stage renal function) and AKIN (Acute Kidney Injury Network) criteria in patients with primary or recurrent ovarian cancer with peritoneal dissemination treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
METHODS
METHODS
One hundred fifty-two patients who were treated between December 2007 and June 2017 were analyzed.
RESULTS
RESULTS
Patients who received previous platinum-based chemotherapy had higher baseline creatinine levels than those who had not (p = 0.05). A total of 11 (7.2%) and 4 (2.6%) patients developed an acute renal dysfunction (ARD) during the postoperative period of cytoreduction and HIPEC according to the RIFLE and AKI criteria respectively. RIFLE detects a higher rate of ARD due to different parameters such as GFR (7.2% versus 2.6%, p = 0.016). Performing ostomy (p = 0.007; OR: 39.320; 95% CI = 2.74-56.13) and using of cisplatin during HIPEC treatment (p = 0.017; OR = 13.619; 95% IC = 1.600-25.95) were factors independently related to a higher rate of ARD.
CONCLUSION
CONCLUSIONS
ARD has a multifactorial origin. Cisplatin was associated with the development of a higher rate of ARD than paclitaxel. Diagnosis of ARD did not correlate with worse survival figures.
Identifiants
pubmed: 34283300
doi: 10.1007/s00423-021-02279-6
pii: 10.1007/s00423-021-02279-6
doi:
Substances chimiques
Cytostatic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2449-2456Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2019) SEER cancer statistics review, 1975–2016. National Cancer Institute, Bethesda. Based on November 2018 SEER data submission, posted to the SEER web site. https://seer.cancer.gov/csr/1975_2016/
Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Orthod 20:1248–1259
Sugarbaker PH (2000) It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch 67(1):5–8
doi: 10.1272/jnms.67.5
Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955
doi: 10.1056/NEJM199612263352603
Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007
doi: 10.1200/JCO.2001.19.4.1001
Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43
doi: 10.1056/NEJMoa052985
van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240
doi: 10.1056/NEJMoa1708618
Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575
doi: 10.1245/s10434-014-4157-9
Zivanovic O, Chi DS, Filippova O et al (2018) It’s time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecol Oncol 151(3):555–561
doi: 10.1016/j.ygyno.2018.09.007
Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in re- current epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–1575
doi: 10.1245/s10434-014-4157-9
Sin EI-L, Chia CS, Tan GHC et al (2017) Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Int J Hyperth 33(6):690–5
doi: 10.1080/02656736.2017.1293304
Bellomo R, Ronco C, Kellum JA et al (2004) Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:204–212
doi: 10.1186/cc2872
Mehta RL, Kellum JA, Shah SV et al (2007) Acute kidney injury network. Report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31
doi: 10.1186/cc5713
Cascales-Campos P, López-López V, Gil J et al (2016) Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference? Surg Oncol 25(3):164–70
doi: 10.1016/j.suronc.2016.05.010
Cascales-Campos PA, Gil J, Feliciangeli E et al (2015) The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol 22(3):987–993
doi: 10.1245/s10434-014-4049-z
Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221(2):124–32
doi: 10.1097/00000658-199502000-00002
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42
doi: 10.1097/00000658-199501000-00004
Lassnigg A, Schmidlin D, Mouhieddine M et al (2004) Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 15:1597–1605
doi: 10.1097/01.ASN.0000130340.93930.DD
Ceresoli M, Coccolini F, Ansaloni L (2016) HIPEC and nephrotoxicity: a cisplatin induced effect? Eur J Surg Oncol 42(6):909–910
doi: 10.1016/j.ejso.2015.08.174
Chertow GM, Burdick E, Honour M et al (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16:3365–3370
doi: 10.1681/ASN.2004090740
Joannidis M, Metnitz B, Bauer P et al (2009) Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med 35(10):1692–1702
doi: 10.1007/s00134-009-1530-4
Glehen O, Osinsky D, Cotte E et al (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10(8):863–869
doi: 10.1245/ASO.2003.01.018
Arjona-Sánchez A, Cadenas-Febres A, Cabrera-Bermon J, Muñoz-Casares FC, Casado-Adam A, Sánchez-Hidalgo JM et al (2016) Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances. Eur J Surg Oncol 42(6):869–876
doi: 10.1016/j.ejso.2015.12.016
Cata JP, Zavala AM, Meter AV, Williams UU, Soliz J, Hernandez M et al (2018) Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study. Int J Hyperth 34(5):538–544
doi: 10.1080/02656736.2017.1368096
Takemoto M, Kuroda M, Urano M et al (2003) The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumors. Int J Hyperthermia 19(2):193–203
doi: 10.1080/0265673021000035235
Cashin PH, Ehrsson H, Wallin I et al (2013) Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. Eur J Clin Pharmacol 69(3):533–540
doi: 10.1007/s00228-012-1405-4
Cotte E, Colomban O, Guitton J et al (2011) Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitonealchemotherapy using a closed abdominal procedure. J Clin Pharmacol 51:9–18
doi: 10.1177/0091270009360980
Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T (2014) The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail 36(10):1486–1491
doi: 10.3109/0886022X.2014.949758
Kapoor R, Robinson KA, Cata JP, Owusu-Agyemang P, Soliz JM, Hernandez M et al (2019) Assessment of nephrotoxicity associated with combined cisplatin and mitomycin C usage in laparoscopic hyperthermic intraperitoneal chemotherapy. Null 36(1):492–7